Arrowhead Pharmaceuticals director sells $1 million in stock amid new analyst coverage

Arrowhead Pharmaceuticals is seeing significant activity regarding its stock and analyst outlooks. Director Michael S. Perry sold 11,600 shares of common stock on August 18, 2026, in transactions totaling approximately $1 million. Following the sale, Perry retains 111,459 shares directly held, representing roughly 0.0791% of the company's equity.

In terms of market analysis, Citigroup has initiated coverage on Arrowhead Pharmaceuticals with a ‘buy’ rating and a price target of $108.00, suggesting a potential upside of over 25% from recent levels. This follows a variety of other analyst assessments; while some firms like Chardan Capital and Stifel Nicolaus maintain ‘buy’ ratings, others such as Weiss Ratings have issued ‘sell’ ratings. The company currently holds a consensus rating of ‘Moderate Buy’ with an average target price of $99.15.